Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review

Table 1

Characteristics of cerebrospinal fluid analysis in reported cases of longitudinal extensive transverse myelitis (LEMT) post COVID-19 vaccine.

Author/country	Type of vaccine	CSF protein mg/dL	CSF glucose mg/dL	CSF white blood cells x u/L	CSF OCB	Serum OCB
Our case; Brazil	AstraZeneca	56.4	56 (123 serum)	205 (88% lymphocytes)	Positive	Positive
Pagenkopf and Sudmeyer [10]; ermany	AstraZeneca	1400; 7 days after normal	Decreased; 7 days after normal	481 (67% neutrophil); 7 days after 76 (100% lymphocyte)	Negative	Negative
Notghi et al. [11]; United Kingdom	AstraZeneca	168.0	76 (140 serum)	11 (100% lymphocytes)	Positive	Positive
Yong Tan et al. [12]; Malaysia	AstraZeneca	54.6	31 (56 serum)	<5	Negative	Negative
Hsiao et al. [13]; Taiwan	AstraZeneca	44.3	No data	11 (100% lymphocytes)	No data	No data
McLean and Trefts [14]; USA	Pfizer	<40	Normal	<5	Positive	Positive
Ali Alshararni [15] Saudi Arabia	Pfizer	62.1	46 (- serum)	No data	No data	No data
Gao et al. [16]; Taiwan	Moderna	57.2	71 (117 serum)	15 (73% neutrophil)	Negative	Negative
Khan et al. [17]; USA	Moderna	56.0	77 (125 serum)	2	Positive	Positive
Tahir et al. [18]; USA	Johnson and Johnson	43	71	227 (96% lymphocytes)	Negative	Negative
Erdem et al. [19]; Turkey	CoronaVac	56.0	104 (150 serum)	2	Negative	Negative